- Conditions
- New Onset Generalized Myasthenia Gravis (gMG)
- Interventions
- Efgartigimod PH20 SC
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 18
- States / cities
- La Jolla, California • Rancho Mirage, California • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 22, 2026, 12:05 AM EDT